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Objectives: Approximately one fourth of all patients with stage I non-small- 
cell lung cancer die of tumor recurrence, despite radical removal of their 
tumors. We thus tried to detect micrometastasis in the regional lymph 
nodes indicated to be tumor free by conventional histopathologic methods 
in patients with non-small-cell lung cancer by using immunohistochemical 
staining for p53 protein. We also investigated the relation between micro- 
metastatic p53-positive cells in the lymph nodes and the prognosis of the 
patients. Methods: Samples from 480 regional lymph nodes were taken from 
47 patients who underwent pulmonary resection for non-small-cell ung 
cancer and whose primary lesions were positive for p53 immunohistochem- 
ical staining. These samples were fixed in formalin and embedded in 
paraffin. We used p53 immunohistochemical staining to detect micrometa- 
static tumor cells in the lymph nodes. Results: Cells positive for p53 protein 
were found in 14 of 31 (45%) patients with a negative pathologic lymph node 
status and in 26 of 315 (8.3%) lymph nodes in these patients. The 
proportion of patients with micrometastasis who survived was also signif- 
icantly lower than the proportion of patients without micrometastasis who 
survived (p = 0.0001). Conclusions: Immunohistochemical staining for the 
p53 protein offers a rapid, sensitive, and useful way of detecting for 
micrometastasis to the regional ymph nodes in patients with non-small- 
cell lung cancer that is positive for p53 staining. The patients with such 
micrometastases have a poor prognosis and thus need to be carefully 
followed up after the initial pulmonary resection. (J Thorac Cardiovasc 
Surg 1997;114:339-46) 
D espite undergoing radical surgery, about one fourth of all patients with stage I non-small-cell 
lung cancer (NSCLC) die of disease recurrence. 1 
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This poor prognosis suggests the occurrence of 
micrometastasis, which often takes place before the 
primary operation and therefore cannot be assessed 
by routine clinical examinations. As a result, it may 
be important o detect occult micrometastasis so
that disease recurrence can be predicted more ac- 
curately. 
Currently, micrometastasis can be detected by 
immunohistochemical ( IHC) staining or genetic 
methods. Several investigators 2-6 have recently used 
these techniques to detect micrometastasis of vari- 
ous malignant tumors in the lymph nodes, while also 
reporting their prognostic significance. In carcinoma 
of the breast, micrometastasis to the axillary lymph 
nodes was detected by using IHC staining with 
monoclonal antibodies against such epithelial anti- 
gens as cytokeratin and epithelial membrane anti- 
gen, and a significant correlation between the detec- 
tion of micrometastasis and a poor prognosis was 
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Table I. Clinical characteristics of the patients and 
the distribution of positive p53 IHC staining in the 
resected NSCLC 
No. of patients 
with positive 
p53 IHC staining 
Background factors No. of 
of the patients patients No. % p Value* 
Total 101 47 47 
Age (yr) 0.2701 
>60 66 34 52 
_-__60 35 14 40 
Sex 0.7024 
Male 69 33 48 
Female 32 14 44 
Histology 0.1467 
Adenocarcinoma 56 22 39 1 0.0431 
Squamous cell 38 23 61 J" 
carcinoma 
Large cell 4 2 50 
carcinoma 
Adenosquamous 2 0 0 
carcinoma 
Mucoepidermoid 1 0 0 
carcinoma 
Pathologic stage 0.5482 
I 51 25 49 
II 6 1 17 
IIIA 31 15 48 
IIIB 7 4 57 
IV 6 2 33 
T status 0.5707 
T1 29 12 41 
T2 52 23 44 
T3 11 7 64 
T4 9 5 56 
N status 0.2339 
N0 60 31 52 
N1 12 3 25 
N2 29 13 45 
Curability 0.5319 
Complete 88 42 48 
Incomplete 13 5 38 
*~ test. 
thus reported. 2 In colorectal cancer, a genetic diag- 
nosis of micrometastasis to the regional lymph 
nodes using mutant-allele-specific amplification 
(MASA) to detect mutations in K-ras or p53 was 
examined, and the lymph node micrometastasis 
identified by this genetic method was found to be 
significantly correlated with disease recurrence. 3 In 
addition, in esophageal denocarcinoma, p53-posi- 
tive findings on IHC staining of the primary tumor 
and the regional lymph nodes appeared to be asso- 
ciated with a reduced overall survival. 7 In NSCLC, 
an IHC analysis using antibodies against epithelial 
antigens including anticytokeratin a d Ber-EP4 for 
detecting disseminated cancer cells in the regional 
lymph nodes was performed, and the frequency and 
prognostic significance of micrometastasis was thus 
reported.4, 5 In these reports, micrometastasis in the 
regional ymph nodes was identified in 63% and 
16% of patients with pN0 disease by using anticy- 
tokeratin and Ber-EP4, respectively. Nodal micro- 
metastasis was also associated with a reduced sur- 
vival in the study in which Ber-EP4 was used. The 
detection of micrometastasis in the regional lymph 
nodes of NSCLC using genetic procedures with 
reverse transcriptase-polymerase chain reaction for 
surfactant protein was examined in pulmonary ade- 
nocarcinoma nd micrometastatic nodal involve- 
ment was thus identified in about half of the lymph 
nodes that had been judged to be tumor free 
according to a routine pathologic examination. 6 
The identification of micrometastasis in bone mar- 
row by means of an IHC assay with anticytokeratin 
antibody was done on patients with gastric ancer, and 
micrometastasis in the bone marrow was detected in 
about one third of the patients at the time of the 
primary operation, s The disseminated tumor cells 
were detected with the use of anticytokeratin in the 
bone marrow of patients with esophageal carcinoma, 
and the patients with tumor cells thus found in their 
bone marrow had a significantly shorter survival than 
the corresponding patients without any tumor cells in 
their bone marrow. 9In NSCLC, a similar IHC assay 
was performed with anticytokeratin a tibody to detect 
micrometastasis in the bone marrow, and the micro- 
metastases detected by this method closely correlated 
with a poor prognosis in such patients. 1° The detection 
of micrometastasis not only in the lymph nodes but 
also in the bone marrow is important for predicting the 
prognosis of patients with various malignant diseases. 
Alteration of the p53 tumor suppressor gene is 
one of the most frequent genetic changes in 
NSCLC, and it is mutated in about half of all 
patients with NSCLC. 11-14 An overexpression f p53 
protein is specifically detected in tumor cells con- 
taining a p53 mutation but is not detected in either 
tumor cells without a p53 mutation or nontumor 
cells. 15 Its immunoreactivity is found at a rate 
similar to that of the p53 gene mutations, 12' 16, 17 and 
these characteristics are also preserved in the met- 
astatic regional lymph nodes. 3For these reasons, we 
applied IHC staining of p53 protein in patients with 
positive p53 IHC staining for their primary NSCLC 
to detect micrometastatic tumor cells in the regional 
lymph nodes and also evaluated their prognostic 
significance. 
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Fig. 1. Section of the regional lymph node in a case of primary lung cancer. Three p53 IHC-positive tumor 
cells (arrows) are seen in a background of benign lymphatic ells. One of them, which is located at the 
center of this picture, has the most characteristic deep brown stained nucleus. 
Patients and methods 
Patients. We studied 101 consecutive patients with 
NSCLC ~vho had undergone a surgical resection at the 
Department of Respiratory Surgery in National Oita 
Hospital during the 4-year period from 1987 to 1990. 
Tumor stage, TNM classification, and the curability of the 
operation were classified according to the fourth edition 
of the TNM classification of the International Union 
Against Cancer (1987). The patient characteristics are 
shown in Table I. According to the preoperative clinical 
staging, 57 patients had stage I disease, 4 had stage II, 32 
had stage IIIA, 3 had stage IIIB, and 5 had stage IV 
disease. The 13 patients with an incomplete resection 
included 6 with unresected distant metastasis and 7 with a 
pleural dissemination of the tumor. 
We retrospectively investigated the postoperative 
records of all 101 patients. The patients were examined 
every month within the first year after operation and 
thereafter at 2- to 4-month intervals as a rule. The 
evaluations included a physical examination, chest roent- 
genography, analysis of blood chemistry, and carcinoem- 
bryonic antigen assay. If any symptoms or signs of recur- 
rence appeared in these examinations, further evaluations 
including bronchoscopy, computed tomography, abdomi- 
nal ultrasonography, and a bone scan were performed. 
Only one patient died of respiratory failure within 1 
month after the operation. 
IHC staining. Samples including regional lymph 
nodes or a primary tumor were fixed in formaldehyde 
(formalin) and embedded in paraffin. At first, two slices 
of 4 ~m sections were obtained from samples of the 
primary lesions. The samples were all obtained from the 
widest transected areas of the primary tumors. One was 
for staining with anti-p53 protein antibody. Another 
was for staining with ematoxylin and eosin. After 
paraffin was cleaned from the sections, they were placed 
in a citrate buffer and incubated five times for 5 minutes 
each in a microwave oven for antigen retrieval. They 
were then stained with mouse monoclonal antibody 
DO-1 (Oncogene Science Inc., Cambridge, Mass.) by means 
of the labeled streptavidin-biotin method (DAKO LSAB 
Kit, CA930 13, Dako Corp., Carpinteria, Calif.). 
The sections were then examined for nuclear staining 
under a light microscope. We evaluated p53 immunore- 
activity according to the proportion of the tumor cells in 
which the nuclei were stained. The sections from the 
primary lesions were scored positive when the proportion 
of stained cells was 10% or more. This criterion was based 
on the findings of another eport, as and the concordance 
rate between the DNA analysis and IHC staining was 
relatively constant when this cutoff level was used. 
Next, the lymph node samples from all patients whose 
primary lesions were scored positive with p53 IHC stain- 
ing were sectioned into slices 4/xm thick. Every five slices 
from ten sections were then attached to glass slides and 
p53 IHC staining was done in the same manner. The 
sections from the lymph nodes were scored positive when 
the nuclei of one or more cells within the whole body 
section of the lymph nodes were stained. 
The specimens were examined and checked by three of 
the authors (K.D., K.S., and T.O.) who had no knowledge 
of the patients' characteristics including the routine his- 
topathologic lymph node status (N status). 
Statistical analysis. Differences in several proportions 
were then compared by a 9( 2 test. Survival curves were 
estimated by the Kaplan-Meier method, and any differ- 
ences were analyzed by the log-rank test. The Cox pro- 
portional hazards model was used for a multivariate 
3 4 2 Dobashi et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
September 1997 
Table II. The frequency of lymph node micrometastasis based on p53 IHC staining according to the 
pathological N status 
Negative lymph nodes by pathologic study 
Patients with Lymph 
p53-positive nodes with 
No. of positive nodes No. of p53-positive cells 
Pathologic No. of No. of lymph lymph nodes by lymph nodes 
N status patients nodes pathologic study No. % examined No. % 
pN0 31 315 0 14 45 315 26 8.3 
pN1 3 26 3 1 33 23 1 4.3 
pN2 13 139 38 4 31 101 12 11.9 
Total 47 480 41 19 40 439 39 8.9 
Table Ili. Discrepancy in the nodal status between 
the pathologic study and p53 IHC staining 
No. defined by No. defined by 
Nodal status pathology [HC staining 
NO 31 17 
N1 3 7 






*Forty-seven patients whose primary lesions were positive for p53 IHC 
staining were valuated. 
analysis. The data were considered to be significant when 
the p value was less than 0.05. 
Results 
Overexpression of the p53 protein in the primary 
lesions. Positivities of the IHC stain for p53 protein 
in the primary tumor are shown in Table I according 
to the background factors of the patients. The 
positive rate was 47% in the 101 patients. The rate 
of p53 protein overexpression was not associated 
with age, sex, stage, T status, N status, or curability 
of treatment. The positive rate was significantly 
higher in patients with squamous cell carcinoma 
than in those with adenocarcinoma. In addition, the 
p53 protein overexpression was not correlated with 
patient SUlvival. 
Application of p53 IHC staining for the detection 
of micrometastasis in the lymph node. We exam- 
ined p53 protein overexpression for the detection of 
micrometastatic tumor cells in the regional ymph 
nodes obtained from all 47 patients who had p53- 
positive primary lesions. A small number of tumor 
cells having nuclei that stained for p53 were seen in 
either the subcapsular or medullary sinuses of lymph 
node specimens, as shown in Fig. 1. 
Table IV. A univariate analysis of various 
prognostic factors of 47patients in Table II1 
Five-year 
No. of survival p 
Prognostic factors patients (%) Value 
Age (yr) 0.9861 
>60 34 47 
_-<60 13 46 
Sex 0.4234 
Male 33 42 
Female 14 57 
Histology 0.4148 
Squamous cell carcinoma 23 38 
Non-squamous cell carcinoma 24 54 
T status 0.2531 
T1-2 35 51 
T3-4 12 33 
Pathologic N status 0.0132 
NO 31 58 
N1-2 16 25 
M status 0.0050 
M0 45 49 
MI 2 0 
Curability 0.0012 
Complete 42 52 
Incomplete 5 0 
p53 immunohistochemical N 0.0001 
status 
NO 17 88 
N1-2 30 23 
Prevalence of micrometastatic p53-positive cells 
in the regional lymph nodes. We examined 480 
lymph nodes from the 47 patients described herein. 
A formal systematic dissection of mediastinal lymph 
nodes was performed in 35 patients, and samples of 
the mediastinal lymph nodes were taken in 12. In 19 
(40%) of these 47 patients, p53-positive cells were 
detected in the pathologically negative lymph nodes. 
Of 439 lymph nodes that were negative by conven- 
tional pathologic examination, 39 (8.9%) contained 
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Fig. 2. The survival curves of the patients with pathologic NO disease with and without micrometastasis in 
the regional lymph nodes detected by p53 IHC staining. 
p53-positive cells. Of 315 lymph nodes from the 
patients with pN0 disease, 26 (8.3%) were positive 
for p53 on IHC staining. In the lymph nodes judged 
negative by pathologic examination, the positive 
rates of p53 overexpression were 8.3%, 4.3%, and 
11.9%, respectively, in pN0, pN1, and pN2 disease 
(Table II). 
Of the 31 patients whose regional ymph nodes 
were negative according to a conventional patho- 
logic study, 14 (45%) patients had p53-positive cells 
in their lymph nodes (Table II). Five patients were 
upgraded to N1 status and nine were upgraded to 
N2 status. The details of the differences between the 
pathologic study and p53 IHC staining with regard 
to the N status are shown in Table III. 
Influence of micrometastatic p53-positive cells in 
the lymph node on prognosis. The median survival 
time and 5-year survival of the patients with pN0 
disease and micrometastasis were only 22 months 
and 21%, respectively. On the other hand, those of 
the patients with pN0 disease without micrometas- 
tasis were more than 60 months and 87%, respec- 
tively. Fig. 2 shows the significant difference of 
survival (p = 0.0001) between the patients with pN0 
disease with and without micrometastasis. 
A similar difference was also observed in patients 
with stage I disease. The 5-year survivals of patients 
with and without micrometastasis were 86% and 
30%, respectively, and the difference was statisti- 
cally significant (p = 0.0013) (Fig. 3). The disease- 
free survival curve of the patients who had pN0 
disease without micrometastasis was significantly 
better than that of the patients with micrometastasis 
(p = 0.0018). In addition, in stage I, the disease-flee 
survival curve was significantly better in patients 
without micrometastasis than in those with micro- 
metastasis (p = 0.0343). 
A multivariate analysis was performed to deter- 
mine whether the N status according to p53 IHC 
staining is an independent prognostic factor for 
survival. At first, the effect of several potential 
prognostic factors was analyzed by a univariate 
analysis (Table IV). The pathologic N status, distant 
metastasis, completeness of surgical resection, and 
N status according to p53 IHC staining were all 
statistically significant factors indicative of a poor 
prognosis. Thereafter, a multivariate analysis with a 
Cox regression model was done to determine which 
of these four factors has a predominant impact on 
survival. As shown in Table V, the N status on p53 
IHC staining was found to be an independent and 
predominant prognostic factor (p = 0.0016, relative 
risk 11.4). 
Discussion 
The p53 tumor-suppressor gene mutation is one of 
the most frequent genetic hanges for cancer. 1a'12 It is 
mutated in about half of the various known types of 
malignant diseases including NSCLC. 12' 16,17 The mu- 
tation of the p53 gene in tumor cells produces tabili- 
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Fig. 3. Differences in the survival curves between the patients with stage I disease with and without 
micrometastasis in the regional lymph nodes detected by p53 IHC staining. 
Table V. A multivariate prognostic factor analysis of 47patients in Table III 
Prognostic factors Estimated coefficient Standard error Relative risk 95% CI p Value 
Complete vs incomplete resection 0.74 0.65 2.09 0.58-7.49 0.259 
M0 vs M1 0.84 0.94 2.32 0.37-14.7 0.373 
Pathologic NO vs N1-2 -0.22 0.45 0.80 0.33-1.95 0.622 
p53 IHC NO vs N1-2 2.44 0.77 11.4 2.51-52.0 0.002 
C/, Confidence interval. 
zation and accumulation of the protein in the nuclei, 
which reaches overexpressed l vels detectable by IHC 
staining. 
We used the antibody against p53 protein to 
detect micrometastasis in the regional ymph nodes 
of patients with NSCLC, because it was specifically 
overexpressed in the tumor cells and was undetect- 
able in normal cells because of its short half-life and 
its low amounts. 15 In this study, normal lung tissue 
specimens around the tumors were negative for p53 
IHC staining. 
Our approach enabled us to detect specifically 
micrometastatic umor cells in the lymph nodes. We 
also examined p53 IHC staining in the lymph nodes 
obtained from seven patients with p53-negative pri- 
mary lesions (five in pN0 and two in pN2). No 
positively stained cells were found in the lymph 
nodes of the five patients with pN0 disease, and the 
metastatic lesions in the lymph nodes of the two 
patients with pN2 disease were not stained at all. 
Therefore this method can be used for patients with 
positive p53 staining in the primary tumor, which 
thus includes about half of all patients with NSCLC. 
In our investigation, the overexpression f p53 pro- 
tein was preserved uring metastasis to the regional 
lymph nodes. Their reactivity of the anti-p53 protein 
antibody was positive in all 41 lymph nodes with a 
pN1 and pN2 status. When the hematoxylin and 
eosin sections were reviewed after a p53 IHC exam- 
ination, only two sections could be diagnosed as 
positive for micrometastasis among the 39 p53- 
positive lymph nodes diagnosed to be negative by 
pathologic study. 
Currently, several antibodies against antigens pe- 
cific for epithelial cells, including cytokeratins, are 
used for the detection of micrometastases. 2' 4, 5, 8, 10 
Chen and associates 4 reported that lymph node 
micrometastasis was detected by means of an anti- 
cytokeratin antibody in 63% of patients with pN0 
disease who had NSCLC. However, the antibodies 
against cytokeratins are specific for all epithelial 
cells but not for tumor cells, and thus they might 
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react positively with nontumor cells. 4' 5 Passlick and 
coworkers 5 used a monoclonal antibody named Ber- 
EP4 to stain against wo glycopolypeptides, both on 
the surface and in the cytoplasm of epithelial cells. 
This antibody was thus suggested to be more specific 
against cancer cells, and it also demonstrated nodal 
micrometastasis in 16% of the patients with pN0 
disease and in 6.2% of the lymph nodes that were 
negative by routine histopathologic examination. 
Such IHC staining using anticytokeratin and anti- 
epithelial differentiation protein antibodies may 
thus be useful especially in patients with p53-nega- 
tive tumors. 
In our current study, the 5-year survival of the 
patients with pN0 disease and micrometastasis was 
21%. However, the 5-year survival of those without 
micrometastasis was 87% and the difference was 
statistically significant. These results suggested that 
patients with micrometastasis hould be followed up 
carefully regardless of pathologic N status. 
Martini and colleagues t investigated the pattern 
of recurrences in resected stage I lung cancer and 
proved that about three fourths of the recurrences 
were hematogenous distant metastases. Among our 
25 patients with stage I disease and p53-positive 
IHC staining in the primary tumor, four patients had 
a recurrence. All four recurrences were distant 
metastases. Furthermore, among our 31 patients 
with pN0 disease and p53-positive IHC staining in 
the primary tumor, all seven patients with recur- 
rence had distant metastases, although five of them 
did concurrently have local recurrences (data not 
shown). Pantel and associates 1° reported that micro- 
metastasis n the bone marrow in patients with pN0 
disease and NSCLC was an indicator for poor 
prognosis. I° Distant metastases are likely to occur 
frequently in patients with micrometastasis in the 
bone marrow. The reason that the presence of 
micrometastasis in the regional ymph nodes indi- 
cates the prevalence of distant metastasis remains to 
be clarified. Our preliminary analysis using anticy- 
tokeratin antibody and anti-p53 antibody regarding 
the relationship between p53 overexpression in the 
primary tumor and the detection of micrometastasis 
in the bone marrow suggested that micrometastatic 
cancer cells were more prevalent in the bone mar- 
row of patients with a tumor having p53 protein 
overexpression than in those with a tumor having no 
p53 overexpression. 
Various genetic approaches are expected to be 
used in the future for the detection of micrometas- 
tasis in the lymph nodes. Micrometastasis n the 
lymph nodes of pulmonary adenocarcinoma were 
detected by means of reverse transcriptase-poly- 
merase chain reaction with primers specific for 
surfactant protein. 6A genetic diagnosis of lymphatic 
micrometastasis in colorectal cancer using mutant- 
allele-specific amplification (MASA) for p53 gene 
mutation has also been tried. 3 Such genetic diag- 
noses may also be useful in predicting the prognosis 
of patients. Both IHC and genetic DNA detection of 
p53 mutation seem to have the same ability to detect 
micrometastasis in the lymph nodes. In this study, 
we did not perform a molecular analysis. Harris and 
Hollstein lI reported that more than 90% of the 
tumors with p53 missense mutations were positive in 
the test for abnormal accumulation of p53, whereas 
fewer than 20% in the tumors with p53 mutations 
are undetectable by p53 IHC staining owing to 
nonsense mutations. They also suggested that al- 
though the concordance between p53 gene mutation 
and the accumulation of p53 protein cannot here- 
fore be perfect, immunoreactivity does appear to be 
an approximate indicator of the tumors with an 
altered p53 function. 11 
In conclusion, IHC staining of p53 is considered 
to be a rapid and sensitive method to detect meta- 
static tumor cells in the lymph nodes. Micrometas- 
tasis in the lymph nodes detected by this procedure 
is an important indicator for prognosis after an 
initial pulmonary resection. 
We thank Miki Kiyofuji and Kinue Nishida for helpful 
work and Dr. Brian Quinn for critical comments. 
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